Current Report Filing (8-k)
March 08 2017 - 7:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): March
8, 2017
Creative Medical
Technology Holdings, Inc.
(Exact name of registrant
as specified in its charter)
Nevada
|
|
000-53500
|
|
87-0622284
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
|
|
|
|
2017 W Peoria Avenue, Phoenix, AZ 85029
|
|
|
|
|
(Address
of principal executive offices)
|
|
|
Registrant’s
telephone number, including area code:
(602) 680-7439
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On March 8, 2017, Creative Medical Technology
Holdings, Inc. (the “
Company
”) issued a press release announcing the appointment of Dr. Thomas Ichim as Chief
Scientific Officer.
The press release, furnished as Exhibit
99.1 to this Form 8-K, may contain forward-looking statements. Such forward-looking statements are based on information presently
available to the registrant’s management and are current only as of the date made. Actual results could also differ materially
from those anticipated as a result of a number of factors, including, but not limited to, those discussed in the registrant’s
Annual Report on Form 10-K for the year ended December 31, 2016, and subsequent reports filed by the Company with the Commission.
For those reasons, undue reliance should not be placed on any forward-looking statement. The Company assumes no duty or obligation
to update or revise any forward-looking statement, although it may do so from time to time as management believes is warranted
or as may be required by applicable securities law. Any such updates or revisions may be made by the registrant by filing reports
with the Commission, through the issuance of press releases or by other methods of public disclosure.
|
Item 9.01.
|
Financial Statements and Exhibits
|
Exhibit No.
|
|
Description
|
99.1
|
|
Press Release dated March 8, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Creative Medical Technology Holdings, Inc.
|
|
|
|
|
Date: March 8, 2017
|
By:
|
/s/ Timothy Warbington
|
|
|
Timothy Warbington, Chief Executive Officer
|